StockData
Longeveron Inc. logo

Longeveron Inc. (LGVN) stock

LGVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$1.66−0.16 (-8.79%)

Close on Nov 20, 2026Market cap $52.92MP/E –Yield –

Longeveron operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Longeveron's operating income for the twelve months ending Jun 30, 2026 was -$23.66M. For fiscal 2025 it was -$23.29M. The highest annual figure on record is -$3.78M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$23.29M–
FY2024Dec 31, 2024-$16.52M–
FY2023Dec 31, 2023-$21.03M–
FY2022Dec 31, 2022-$18.04M–
FY2021Dec 31, 2021-$17.46M–
FY2020Dec 31, 2020-$3.78M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.17M–
Q1 FY2026Mar 31, 2026-$4.78M–
Q4 FY2025Dec 31, 2025-$5.40M–
Q3 FY2025Sep 30, 2025-$7.31M–
Q2 FY2025Jun 30, 2025-$5.40M–
Q1 FY2025Mar 31, 2025-$5.18M–
Q4 FY2024Dec 31, 2024-$4.28M–
Q3 FY2024Sep 30, 2024-$4.65M–
Q2 FY2024Jun 30, 2024-$3.50M–
Q1 FY2024Mar 31, 2024-$4.09M–
Q4 FY2023Dec 31, 2023-$5.44M–
Q3 FY2023Sep 30, 2023-$5.16M–
Q2 FY2023Jun 30, 2023-$5.71M–
Q1 FY2023Mar 31, 2023-$4.72M–
Q2 FY2022Jun 30, 2022-$4.22M–
Q1 FY2022Mar 31, 2022-$3.39M–
Q4 FY2021Dec 31, 2021-$4.03M–
Q3 FY2021Sep 30, 2021-$4.91M–
Q2 FY2021Jun 30, 2021-$5.06M–
Q1 FY2021Mar 31, 2021-$3.46M–
Q4 FY2020Dec 31, 2020-$1.38M–
Q3 FY2020Sep 30, 2020-$958.00K–
Q2 FY2020Jun 30, 2020-$1.23M–
Q1 FY2020Mar 31, 2020-$213.00K–

More Longeveron figures

See a number that looks wrong?